CellaVision evaluates new product for the veterinary market


CellaVision, which develops and sells digital morphology products for
the routine analysis of blood and other body fluids, is adapting its
current range of products for use in veterinary laboratories. Several
veterinary laboratories are evaluating CellaVision's products in
Sweden and the US. The results are expected before the end of the
year 2009.

"The veterinary market is showing interest in our concept and our
products for quicker and more standardized analytical results, which
may open up an entirely new market for our hematology products," says
Yvonne Mårtensson, CEO of CellaVision. "A number of Swedish
veterinary hospitals have evaluated our product with positive
outcomes. However, we will wait to decide on when to launch our
product until the US market has made an evaluation. We are expecting
results to come in by the end of the year."

Veterinary laboratories can use the CellaVision analyzers to assess
blood cells as well as create digital images of slide areas,
so-called Digital Slides. Blood analysis is an important part of
diagnosing a number of diseases, including different types of
infections and blood diseases. The benefits of using CellaVision's
products are the same as when using them on human blood, namely
quicker and more standardized results, digital archiving of results
in patient journals, as well as the transfer of digital images to
experts outside the laboratory.

One of the clinical studies was performed at the veterinary
laboratory at the Swedish University of Agricultural Sciences (SLU)
in Uppsala. The response was positive:

"Being able to make fast and correct diagnoses is of the essence for
veterinarians," says Inger Lilliehöök, veterinarian at SLU. "By using
CellaVision's technology, veterinary hospitals can improve the
quality of analytical results and increase the ability to diagnose.
In that way, pets can be offered the appropriate care."

In general, there is potential for medical technology products in the
veterinary market. In Sweden there are four regional veterinary
hospitals, 24 medium-sized hospitals, and a number of small animal
clinics. One in four Swedish households owns a pet, accounting for
the 1.5 million cats and 950 000 dogs in the country. In the US there
are around 3000 veterinary hospitals with its own laboratory and 50
large-sized commercial veterinary laboratories. More than one third
of the American households own a pet. The number of cats is
approximately 90 million and dogs 73 million.


For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 46 286 44 01. E-mail: yvonne.martensson@cellavision.com


About CellaVision
CellaVision AB develops, markets, and sells market leading image
analysis based systems for routine analysis of blood and other body
fluids. The company has a core competence in development of software
and hardware for automatic image analysis of cells and cell changes
for applications in health and medical care. The company develops and
markets systems for automatic differentials of white blood cells and
red morphology, and software for education and quality assurance of
differentials. The company's associates have expertise in advanced
imaging analysis, artificial intelligence, and automated microscopy.

The company headquarters are in Lund, Sweden. The company also has
subsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan.
For more information, visit www.cellavision.com.

CellaVision's share is listed on First North Premier at the OMX
Stockholm Stock Exchange. The company's Certified Advisor is Remium
AB.